Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 11NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 179Leukemia 162Lymphoma 116Lung Neoplasms 107Carcinoma, Non-Small-Cell Lung 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 97Central Nervous System Neoplasms 84Sarcoma 82Prostatic Neoplasms 81Ovarian Neoplasms 76Colorectal Neoplasms 71Head and Neck Neoplasms 70Leukemia, Myeloid, Acute 60Squamous Cell Carcinoma of Head and Neck 54Rectal Neoplasms 54Neuroblastoma 52Colonic Neoplasms 52Multiple Myeloma 51Uterine Cervical Neoplasms 47Brain Neoplasms 46Lymphoma, Large B-Cell, Diffuse 45Leukemia, Lymphocytic, Chronic, B-Cell 41Carcinoma, Ovarian Epithelial 41Burkitt Lymphoma 41Astrocytoma 40Glioblastoma 39Fallopian Tube Neoplasms 39Neoplasm Metastasis 38Congenital Abnormalities 37Lymphoma, Follicular 36

Interventions

Mental Status and Dementia Tests 1Lomustine 1DNA Methylation 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × NETWORK × Cognition Disorders × Clear all
NCT01290939 2021-02-15

Bevacizumab and Lomustine for Recurrent GBM

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Completed
592 enrolled
CNS

Brain Neoplasms, Cognition Disorders, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡